Adapalene inhibits the growth of triple-negative breast cancer cells by S-phase arrest and potentiates the antitumor efficacy of GDC-0941
Although advances in diagnostics and therapeutics have prolonged the survival of triple-negative breast cancer (TNBC) patients, metastasis, therapeutic resistance, and lack of targeted therapies remain the foremost hurdle in the effective management of TNBC. Thus, evaluation of new therapeutic agent...
Main Authors: | Umar Mehraj, Nissar Ahmad Wani, Abid Hamid, Mustfa Alkhanani, Abdullah Almilaibary, Manzoor Ahmad Mir |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.958443/full |
Similar Items
-
Adapalene and Doxorubicin Synergistically Promote Apoptosis of TNBC Cells by Hyperactivation of the ERK1/2 Pathway Through ROS Induction
by: Umar Mehraj, et al.
Published: (2022-07-01) -
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer
by: Patrick Schöffski, et al.
Published: (2018-09-01) -
Topical retinoid drug Adapalene: A new frontier in cancer treatment
by: Shazia sofi, et al.
Published: (2024-08-01) -
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
by: James D Joseph, et al.
Published: (2016-07-01) -
Assessing the cytotoxicity of phenolic and terpene fractions extracted from Iraqi Prunus arabica against AMJ13 and SK-GT-4 human cancer cell lines [version 3; peer review: 2 approved, 1 approved with reservations]
by: Abdulkareem Hameed Abd, et al.
Published: (2024-09-01)